Metabolic consequences of perioperative oral carbohydrates in breast cancer patients - an explorative study

BMC Cancer. 2019 Dec 4;19(1):1183. doi: 10.1186/s12885-019-6393-7.

Abstract

Background: The metabolic consequences of preoperative carbohydrate load in breast cancer patients are not known. The present explorative study investigated the systemic and tumor metabolic changes after preoperative per-oral carbohydrate load and their influence on tumor characteristics and survival.

Methods: The study setting was on university hospital level with primary and secondary care functions in south-west Norway. Serum and tumor tissue were sampled from a population-based cohort of 60 patients with operable breast cancer who were randomized to either per-oral carbohydrate load (preOp™; n = 25) or standard pre-operative fasting (n = 35) before surgery. Magnetic resonance (MR) metabolomics was performed on serum samples from all patients and high-resolution magic angle spinning (HR-MAS) MR analysis on 13 tumor samples available from the fasting group and 16 tumor samples from the carbohydrate group.

Results: Fourteen of 28 metabolites were differently expressed between fasting and carbohydrate groups. Partial least squares discriminant analysis showed a significant difference in the metabolic profile between the fasting and carbohydrate groups, compatible with the endocrine effects of insulin (i.e., increased serum-lactate and pyruvate and decreased ketone bodies and amino acids in the carbohydrate group). Among ER-positive tumors (n = 18), glutathione was significantly elevated in the carbohydrate group compared to the fasting group (p = 0.002), with a positive correlation between preoperative S-insulin levels and the glutathione content in tumors (r = 0.680; p = 0.002). In all tumors (n = 29), glutamate was increased in tumors with high proliferation (t-test; p = 0.009), independent of intervention group. Moreover, there was a positive correlation between tumor size and proliferation markers in the carbohydrate group only. Patients with ER-positive / T2 tumors and high tumor glutathione (≥1.09), high S-lactate (≥56.9), and high S-pyruvate (≥12.5) had inferior clinical outcomes regarding relapse-free survival, breast cancer-specific survival, and overall survival. Moreover, Integrated Pathway Analysis (IPA) in serum revealed activation of five major anabolic metabolic networks contributing to proliferation and growth.

Conclusions: Preoperative carbohydrate load increases systemic levels of lactate and pyruvate and tumor levels of glutathione and glutamate in ER-positive patients. These biological changes may contribute to the inferior clinical outcomes observed in luminal T2 breast cancer patients.

Trial of registration: ClinicalTrials.gov; NCT03886389. Retrospectively registered March 22, 2019.

Keywords: Breast cancer; Carbohydrate load; Clinical outcome; Fasting state; Insulin; Insulin c-peptide; Ketonic bodies; Proliferation; S-lactate; S-pyruvate; Tumor glutamate; Tumor glutathione.

Publication types

  • Randomized Controlled Trial

MeSH terms

  • Biomarkers, Tumor / metabolism
  • Breast Neoplasms / metabolism
  • Breast Neoplasms / pathology
  • Breast Neoplasms / surgery*
  • Cell Proliferation
  • Dietary Carbohydrates / administration & dosage*
  • Dietary Carbohydrates / metabolism*
  • Fasting
  • Female
  • Hospitals, University
  • Humans
  • Magnetic Resonance Spectroscopy
  • Metabolome
  • Middle Aged
  • Norway
  • Perioperative Period
  • Receptors, Estrogen / metabolism
  • Treatment Outcome
  • Tumor Burden

Substances

  • Biomarkers, Tumor
  • Dietary Carbohydrates
  • Receptors, Estrogen

Associated data

  • ClinicalTrials.gov/NCT03886389